Search
From Date :
To Date :
Serivce :
Query :
Keywords :
 ( Seprate With , )
US body says gene therapy may be more cost effective for spinal muscular atrophy
Biogen Inc.’s Spinraza treatment for spinal muscular atrophy and Swiss drugmaker Novartis AG’s experimental gene therapy are both expensive, but the gene therapy could be more cost effective once more is known about its US price and long-term success rates, a preliminary report from an independent US nonprofit organization said.
New figures on muscular dystrophy disorders
Researchers in public health reported in the first broad study in the United States the frequency of two muscle-weakness disorders that strike mostly boys: Duchenne muscular dystrophy and Becker muscular dystrophy.

Page Generated in 0/6101 sec